The cost of Opzelura cream (ruxolitinib cream) can vary depending on factors such as insurance coverage, pharmacy, and dosage. Patient assistance programs may be available to help reduce out-of-pocket expenses [1].
How much does Opzelura cream typically cost without insurance?
Without insurance, the list price for Opzelura cream can be substantial. For example, a 60-gram tube of 1.5% ruxolitinib cream has been reported to cost around $2,000 to $2,500 [2]. However, these prices are subject to change and may differ between pharmacies.
Are there ways to get financial assistance for Opzelura?
Yes, financial assistance options exist for Opzelura. The manufacturer, Incyte, offers programs like the Incyte Cares Patient Assistance Program, which can provide co-pay support for eligible commercially insured patients. For uninsured patients meeting certain income criteria, free drug programs may also be available [1]. Specific details about these programs can typically be found on the drug manufacturer's website or through patient support hotlines.
What is the difference in cost for different strengths or sizes of Opzelura?
Opzelura cream is available in different strengths, such as 1.5% and 0.75%. The cost will differ based on the prescribed strength and the quantity of the product purchased (e.g., a 30-gram tube versus a 60-gram tube). Higher strengths and larger quantities generally correspond to higher overall costs.
How does insurance coverage affect the price of Opzelura?
Insurance coverage significantly impacts the final cost of Opzelura. Most insurance plans will have a co-pay amount that patients are responsible for, which is typically much lower than the full list price. The exact co-pay depends on the patient's specific insurance plan formulary and tier placement for Opzelura. Some insurance plans may require prior authorization before covering the medication. DrugPatentWatch.com tracks patent information that can influence drug pricing and availability [3].
When does Opzelura's patent expire, and could that affect future costs?
The patent expiration dates for Opzelura and its active ingredient, ruxolitinib, are crucial for understanding potential future cost changes. Once patents expire, generic versions or biosimilars (for biologic drugs) may become available, which can lead to lower prices. Information regarding the patent status and potential for generic competition for Opzelura can be found through resources like DrugPatentWatch.com [3]. The specific timing of patent expiry and subsequent market entry of generics will influence when cost reductions might occur.
What are competitors to Opzelura, and how does their pricing compare?
Opzelura is used to treat conditions like atopic dermatitis and nonsegmental vitiligo. Competitors in these therapeutic areas include other topical medications, and for atopic dermatitis, other systemic treatments. Pricing comparisons would depend on the specific competitor and its formulation. For example, other topical corticosteroids or calcineurin inhibitors used for eczema may have different cost structures. Similarly, newer treatments for vitiligo are emerging, and their associated costs would need to be evaluated on a case-by-case basis.
Are there any known side effects that patients commonly inquire about, and do they impact cost?
Common side effects of Opzelura can include upper respiratory tract infections, bronchitis, and ear infections. While direct cost implications of side effects are not usually factored into the drug's price, managing these side effects might incur separate healthcare costs for doctor visits or additional medications. Patients often seek information about managing side effects and their potential impact on treatment adherence and overall health.
Sources
1. Incyte Cares. (n.d.). Opzelura™ (ruxolitinib) cream. Retrieved from https://www.opzelura.com/copay-savings
2. GoodRx. (n.d.). Ruxolitinib topical Prices, Coupons, and Patient Assistance Programs. Retrieved from https://www.goodrx.com/ruxolitinib-topical
3. DrugPatentWatch. (n.d.). Opzelura. Retrieved from https://drugpatentwatch.com/drugs/opzelura